Profile data is unavailable for this security.
About the company
Life Science REIT plc is a closed-ended real estate investment trust. The Company’s investment objective is to provide shareholders with an attractive level of total return. It seeks to invests in a diversified portfolio of properties across the United Kingdom, which are typically leased or intended to be leased to tenants operating in, or providing a benefit to, the life science sector. It acquires or develops properties, such as wet and dry laboratories, offices, incubators and co-working space, manufacturing and testing facilities and data centers. The Company retains flexibility to acquire individual buildings, a group of buildings across a single science park or the entirety of a science park. It also includes purchasing or developing buildings that are leased or intended to be leased to occupiers providing ancillary services to employees of companies operating in, or providing a benefit to, the life science sector. Its investment adviser is Ironstone Asset Management Limited.
- Revenue in GBP (TTM)21.04m
- Net income in GBP-30.67m
- Incorporated2021
- Employees0.00
- LocationLife Science REIT PLC55 Wells StreetLONDON W1T 3PTUnited KingdomGBR
- Phone+44 139 247 7500
- Websitehttps://lifesciencereit.co.uk/
Profile
| Management group(s) | Ironstone Asset Management Limited |
|---|---|
| AIC sector | Property - UK Commercial |
| ISIN | GB00BP5X4Q29 |
| Launch date | 19 Nov 2021 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | GBP |
Objective
The Company will seek to achieve its investment objective by investing in a diversified portfolio of properties across the UK which are typically leased or intended to be leased to tenants operating in, or providing a benefit to, the life science sector. Life science is the branch of sciences concerned with the study of living organisms. This encompasses the study of the breadth of life processes, and the structure and behaviour of living things. Companies operating in the life science sector include, but are not limited to, those involved in the innovation, development and/or production of assets directly or indirectly for human health purposes.
Managed by
| Stephen Barrow, Simon Farnsworth, Pippa Stacey, Simon Hope, David Lewis, Matthew Barker, Ian Harris |
|---|
Management & contract fees
The advisory fee, payable quarterly, is based on the lower of NAV or average market capitalisation at 1% up to GBP 500m, 0.9% up to GBP 1bn, and 0.75% above GBP 1bn. The Investment Adviser’s four-year term is terminable on 24 months’ notice from the fourth anniversary of Admission.
| Holder | Shares | % Held |
|---|---|---|
| Rathbones Investment Management Ltd.as of 03 Nov 2025 | 48.95m | 13.99% |
| Schroder & Co. Ltd.as of 28 Jan 2026 | 33.09m | 9.45% |
| Glazer Capital LLCas of 30 Jan 2026 | 24.59m | 7.03% |
| Merrill Lynch International (Investment Management)as of 30 Jan 2026 | 18.01m | 5.15% |
| UBS Asset Management Switzerland AGas of 30 Jan 2026 | 17.87m | 5.11% |
| Soci�t� G�n�rale Gestion SAas of 10 Feb 2026 | 15.68m | 4.48% |
| Jefferies International Ltd. (Investment Management)as of 11 Feb 2026 | 15.24m | 4.36% |
| Harwood Capital LLPas of 27 Jan 2026 | 13.00m | 3.71% |
| Legal & General Investment Management Ltd.as of 30 Jan 2026 | 12.93m | 3.69% |
| Dowgate Capital Ltd.as of 03 Nov 2025 | 12.69m | 3.63% |
